Literature DB >> 12493641

Functional characterization of the lectin pathway of complement in human serum.

Anja Roos1, Lee H Bouwman, Jeric Munoz, Tahlita Zuiverloon, Maria C Faber-Krol, Francien C Fallaux-van den Houten, Ngaisah Klar-Mohamad, C Erik Hack, Marcel G Tilanus, Mohamed R Daha.   

Abstract

Mannan-binding lectin (MBL) is a major initiator of the lectin pathway (LP) of complement. Polymorphisms in exon 1 of the MBL gene are associated with impaired MBL function and infections. Functional assays to assess the activity of the classical pathway (CP) and the alternative pathway (AP) of complement in serum are broadly used in patient diagnostics. We have now developed a functional LP assay that enables the specific quantification of autologous MBL-dependent complement activation in human serum. Complement activation was assessed by ELISA using coated mannan to assess the LP and coated IgM to assess the CP. Normal human serum (NHS) contains IgG, IgA and IgM antibodies against mannan, as shown by ELISA. These antibodies are likely to induce CP activation. Using C1q-blocking and MBL-blocking mAb, it was confirmed that both the LP and the CP contribute to complement activation by mannan. In order to quantify LP activity without interference of the CP, LP activity was measured in serum in the presence of C1q-blocking Ab. Activation of serum on coated IgM via the CP resulted in a dose-dependent deposition of C1q, C4, C3, and C5b-9. This activation and subsequent complement deposition was completely inhibited by the C1q-blocking mAb 2204 and by polyclonal Fab anti-C1q Ab. Evaluation of the LP in the presence of mAb 2204 showed a strong dose-dependent deposition of C4, C3, and C5b-9 using serum from MBL-wildtype (AA) but not MBL-mutant donors (AB or BB genotype), indicating that complement activation under these conditions is MBL-dependent and C1q-independent. Donors with different MBL genotypes were identified using a newly developed oligonucleotide ligation assay (OLA) for detection of MBL exon 1 polymorphisms. We describe a novel functional assay that enables quantification of autologous complement activation via the LP in full human serum up to the formation of the membrane attack complex. This assay offers novel possibilities for patient diagnostics as well as for the study of disease association with the LP.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12493641     DOI: 10.1016/s0161-5890(02)00254-7

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  50 in total

1.  The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation.

Authors:  M Harboe; G Ulvund; L Vien; M Fung; T E Mollnes
Journal:  Clin Exp Immunol       Date:  2004-12       Impact factor: 4.330

2.  Convertase inhibitory properties of Staphylococcal extracellular complement-binding protein.

Authors:  Ilse Jongerius; Brandon L Garcia; Brian V Geisbrecht; Jos A G van Strijp; Suzan H M Rooijakkers
Journal:  J Biol Chem       Date:  2010-03-19       Impact factor: 5.157

3.  Logarithmic phase Escherichia coli K1 efficiently avoids serum killing by promoting C4bp-mediated C3b and C4b degradation.

Authors:  David G Wooster; Ravi Maruvada; Anna M Blom; Nemani V Prasadarao
Journal:  Immunology       Date:  2006-04       Impact factor: 7.397

4.  Design of a complement mannose-binding lectin pathway-specific activation system applicable at low serum dilutions.

Authors:  M Harboe; P Garred; M S Borgen; G L Stahl; A Roos; T E Mollnes
Journal:  Clin Exp Immunol       Date:  2006-06       Impact factor: 4.330

5.  Structural basis for therapeutic inhibition of complement C5.

Authors:  Matthijs M Jore; Steven Johnson; Devon Sheppard; Natalie M Barber; Yang I Li; Miles A Nunn; Hans Elmlund; Susan M Lea
Journal:  Nat Struct Mol Biol       Date:  2016-03-28       Impact factor: 15.369

6.  Differential complement activation pathways promote C3b deposition on native and acetylated LDL thereby inducing lipoprotein binding to the complement receptor 1.

Authors:  Boudewijn Klop; Pieter van der Pol; Robin van Bruggen; Yanan Wang; Marijke A de Vries; Selvetta van Santen; Joseph O'Flynn; Gert-Jan M van de Geijn; Tjin L Njo; Hans W Janssen; Peter de Man; J Wouter Jukema; Ton J Rabelink; Patrick C N Rensen; Cees van Kooten; Manuel Castro Cabezas
Journal:  J Biol Chem       Date:  2014-10-27       Impact factor: 5.157

7.  Complement factor H-related hybrid protein deregulates complement in dense deposit disease.

Authors:  Qian Chen; Michael Wiesener; Hannes U Eberhardt; Andrea Hartmann; Barbara Uzonyi; Michael Kirschfink; Kerstin Amann; Maike Buettner; Tim Goodship; Christian Hugo; Christine Skerka; Peter F Zipfel
Journal:  J Clin Invest       Date:  2013-12-16       Impact factor: 14.808

8.  The structural basis for inhibition of the classical and lectin complement pathways by S. aureus extracellular adherence protein.

Authors:  Jordan L Woehl; Kasra X Ramyar; Benjamin B Katz; John K Walker; Brian V Geisbrecht
Journal:  Protein Sci       Date:  2017-05-31       Impact factor: 6.725

9.  Early complement factors in the local tissue immunocomplex generated during intestinal ischemia/reperfusion injury.

Authors:  Haekyung Lee; Danielle J Green; Lawrence Lai; Yunfang Joan Hou; Jens C Jensenius; David Liu; Cheolho Cheong; Chae Gyu Park; Ming Zhang
Journal:  Mol Immunol       Date:  2009-12-09       Impact factor: 4.407

10.  Functional analysis of Ficolin-3 mediated complement activation.

Authors:  Estrid Hein; Christian Honoré; Mikkel-Ole Skjoedt; Lea Munthe-Fog; Tina Hummelshøj; Peter Garred
Journal:  PLoS One       Date:  2010-11-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.